Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06279234 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT06279234 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 50 participants.
The verdict
NCT06279234, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes mellitus (T2DM) on metformin (Part A) and optionally in non-diabetic participants with obesity (Part B).
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Omeprazole
- DRUG Rosuvastatin
- DRUG PF-06954522
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2025-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06279234
The ClinicalTrials.gov registry entry for NCT06279234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06279234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06279234 about?
NCT06279234 is a clinical study titled "A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes mellitus (T2DM) on metformin (Part A) and optionally in non-diabetic p...
What is the current status of trial NCT06279234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-02-20. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT06279234?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Omeprazole (DRUG), Rosuvastatin (DRUG), PF-06954522 (DRUG).
Who is sponsoring clinical trial NCT06279234?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.